



GlaxoSmithKline Pharmaceuticals Ltd.  
GSK House,  
Dr. Annie Besant Road, Worli,  
Mumbai - 400 030

Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: www.gsk-india.com  
Email: askus@gsk.com

30<sup>th</sup> October 2019

To,

**BSE LIMITED**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sir,

**Subject: Submission of Disclosure on Related Party Transactions**

In Compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018,- we hereby submit the attached Related Party Transactions, on consolidated basis, drawn in accordance with applicable accounting standards for period ended 30<sup>th</sup> September 2019.

Kindly take submission on record.

Yours faithfully

**For GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni  
Vice President – Administration, Real Estate  
& Company Secretary

Pursuant to Regulation 23 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

1 Relationships (during the year):

(i) Shareholders (the GlaxoSmithKline (GSK) Group shareholding) in the Company :

Glaxo Group Limited, U.K.  
 GlaxoSmithKline Pte Limited, Singapore  
 Eskaylab Limited, U.K.  
 Burroughs Wellcome International Limited, U.K.

Holding company / ultimate holding company of the above shareholders

GlaxoSmithKline Plc, U.K.\*  
 GlaxoSmithKline Finance Plc, U.K.\*  
 Setfirst Ltd, U.K.\*  
 SmithKline Beecham Limited, U.K.  
 Wellcome Limited, U.K.\*  
 The Wellcome Foundation Limited, U.K.\*  
 Wellcome Consumer Healthcare Limited, U.K.\*

\* no transactions during the period

(ii) Other related parties in the GlaxoSmithKline (GSK) Group where common control exists and with whom the Company had transactions during the year:

GlaxoSmithKline Asia Private Limited, India  
 GlaxoSmithKline Brasil Ltda, Brazil\*  
 GlaxoSmithKline Consumer Healthcare Limited, India  
 GlaxoSmithKline Biologicals S.A., Belgium  
 GlaxoSmithKline Pharmaceuticals S.A., Belgium  
 GlaxoSmithKline Services Unlimited, U.K.  
 Glaxo Operations UK Limited, U.K.  
 GlaxoSmithKline Export Limited, U.K.  
 GlaxoSmithKline Latin America S.A.\*  
 GlaxoSmithKline Pakistan Limited, Pakistan\*  
 GlaxoSmithKline Research & Development Ltd, U.K.  
 GlaxoSmithKline Pte Limited, Singapore  
 GlaxoSmithKline Corporate Centre, U.S.A.\*  
 GlaxoSmithKline Philippines Inc, Philippines\*  
 GlaxoSmithKline Australia Pty Limited, Australia\*  
 GlaxoSmithKline Trading Services Limited, Ireland  
 GlaxoSmithKline Limited, Hong Kong\*  
 GlaxoSmithKline South Africa (Pty) Ltd, South Africa\*  
 GlaxoSmithKline LLC, U.S.A.\*  
 GlaxoSmithKline Pharmaceutical Nigeria Limited, Nigeria  
 Stiefel India Private Limited, India  
 Glaxo Wellcome Ceylon Ltd., Sri Lanka\*  
 US GMS Financial Services, U.S.A.\*  
 GlaxoSmithKline Inc, Philadelphia\*  
 GlaxoSmithKline Manufacturing SPA, Italy\*  
 GlaxoSmithKline Intellectual Property Limited\*  
 Chiron Behring Vaccines Private Ltd, India (upto February 28, 2019)

\* no transactions during the period

(iii) Directors and members of GSK India Leadership Team :

Directors:

Mr. A. Vaidheesh #  
 Ms. P. Thakur #  
 Mr. R. Krishnaswamy #  
 Ms. R.S. Karnad (w.e.f. April 1, 2019)  
 Mr. N. Kaviratne  
 Mr. P. Bhide  
 Ms. A. Bansal  
 Mr. A.N. Roy  
 Mr. D. Sundaram  
 Mr. R.R. Bjaaj (upto July 24, 2019) \*  
 Mr. S. Williams \*  
 Mr. M. Jones (w.e.f. April 7, 2017 upto July 24, 2018)

GSK India Leadership Team:

Mr. A. Nadkarni (w.e.f. April 17, 2017)  
 Mr. R. D'souza (w.e.f. April 17, 2017)  
 Mr. S. Dheri  
 Ms. S. Choudhary  
 Mr. B. Kotak (w.e.f. June 14, 2017)  
 Mr. A. Iyer (w.e.f. October 13, 2017)  
 Ms. M. Priyam (w.e.f. July 27, 2017)  
 Ms. D. Jakate (w.e.f. February 19, 2018)  
 Mr. S. Balasubramanian (w.e.f. October 01, 2018)  
 Mr. N. Hindia (w.e.f. June 01, 2018)  
 Mr. G. Kotian (w.e.f. October 01, 2018)  
 Mr. N. Sudrik (w.e.f. October 01, 2018)

# Also member of GSK India Leadership Team  
 \* no transactions during the period

2 The following transactions were carried out with the related parties in the ordinary course of business:

(i) Dividend paid to parties referred to in item 1(i) above:

(Rupees in lakhs)

	Period from April 1, 2019 to September 30, 2019
Glaxo Group Limited, U.K.	121,94.10
GlaxoSmithKline Pte Limited, Singapore	95,20.80
Eskaylab Limited, U.K.	23,52.00
Burroughs Wellcome International Limited, U.K.	13,44.00



Related Party disclosures (continued)

(ii) Details relating to parties referred to in Items 1(i) and 1(ii) above:

(Rupees in lakhs)

	Holding company/ultimate	Other companies in
	holding company 1(i)	the GSK Group 1(ii)
	Period from April 1, 2019 to September 30, 2019	Period from April 1, 2019 to September 30, 2019
1 Purchase of materials/traded goods	-	309,82.90
2 Sale of materials/sale of products	-	23.91
3 Expenses recharged to other companies	1.49	12,97.25
4 Expenses recharged by other companies	-	36,75.63
5 Manufacturing charges recovered	-	6,28.18
6 Clinical research and data management recoveries	-	1,04.31
7 Outstanding receivables at the period end	-	28,08.08
8 Outstanding payables at the period end	-	28,43.30

Note: Transactions and balances with its own subsidiary are eliminated upon consolidation

(iii) Details relating to persons referred to in item 1(iii) above:

(Rupees in lakhs)

	Period from April 1, 2019 to September 30, 2019
1 Remuneration/commission/sitting fees	19,92.98

